Dingdang Health reports 8.95 million shares repurchased pending cancellation; issued capital steady at 1.25 billion

Bulletin Express06-12

Dingdang Health Technology Group Ltd. submitted a Next Day Disclosure Return on 12 June 2026, confirming that the company’s issued share capital remains unchanged at 1.25 billion ordinary shares, with no treasury shares outstanding.

Between 19 May and 12 June 2026 the company bought back a cumulative 8.95 million shares that have not yet been cancelled. The daily repurchase prices ranged from HK$0.82 to HK$0.96 per share, implying a cash outlay of roughly HK$8.02 million. The shares represent about 0.71 % of current issued shares.

On 12 June 2026 alone, Dingdang Health repurchased 54,500 shares on the Stock Exchange of Hong Kong at HK$0.90–0.91 per share, spending HK$49,229.85. These shares are designated for cancellation.

Under the share-repurchase mandate approved on 28 May 2025, the company is authorised to buy back up to 131.95 million shares (5.59 % of the share base at the mandate date). To date, 73.77 million shares have been repurchased under this mandate, utilising approximately 55.9 % of the authorised limit.

In line with listing rules, the company is subject to a moratorium on new share issues until 12 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181425717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181425717","market":"hk","top_or_hot":-1,"title":"Dingdang Health reports 8.95 million shares repurchased pending cancellation; issued capital steady at 1.25 billion","media":"Bulletin Express","content":"<p>Dingdang Health Technology Group Ltd. submitted a Next Day Disclosure Return on 12 June 2026, confirming that the company’s issued share capital remains unchanged at 1.25 billion ordinary shares, with no treasury shares outstanding.</p>\n<p>Between 19 May and 12 June 2026 the company bought back a cumulative 8.95 million shares that have not yet been cancelled. The daily repurchase prices ranged from HK$0.82 to HK$0.96 per share, implying a cash outlay of roughly HK$8.02 million. The shares represent about 0.71 % of current issued shares.</p>\n<p>On 12 June 2026 alone, Dingdang Health repurchased 54,500 shares on the Stock Exchange of Hong Kong at HK$0.90–0.91 per share, spending HK$49,229.85. These shares are designated for cancellation.</p>\n<p>Under the share-repurchase mandate approved on 28 May 2025, the company is authorised to buy back up to 131.95 million shares (5.59 % of the share base at the mandate date). To date, 73.77 million shares have been repurchased under this mandate, utilising approximately 55.9 % of the authorised limit.</p>\n<p>In line with listing rules, the company is subject to a moratorium on new share issues until 12 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dingdang Health reports 8.95 million shares repurchased pending cancellation; issued capital steady at 1.25 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDingdang Health reports 8.95 million shares repurchased pending cancellation; issued capital steady at 1.25 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-12 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dingdang Health Technology Group Ltd. submitted a Next Day Disclosure Return on 12 June 2026, confirming that the company’s issued share capital remains unchanged at 1.25 billion ordinary shares, with no treasury shares outstanding.</p>\n<p>Between 19 May and 12 June 2026 the company bought back a cumulative 8.95 million shares that have not yet been cancelled. The daily repurchase prices ranged from HK$0.82 to HK$0.96 per share, implying a cash outlay of roughly HK$8.02 million. The shares represent about 0.71 % of current issued shares.</p>\n<p>On 12 June 2026 alone, Dingdang Health repurchased 54,500 shares on the Stock Exchange of Hong Kong at HK$0.90–0.91 per share, spending HK$49,229.85. These shares are designated for cancellation.</p>\n<p>Under the share-repurchase mandate approved on 28 May 2025, the company is authorised to buy back up to 131.95 million shares (5.59 % of the share base at the mandate date). To date, 73.77 million shares have been repurchased under this mandate, utilising approximately 55.9 % of the authorised limit.</p>\n<p>In line with listing rules, the company is subject to a moratorium on new share issues until 12 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09886","symbol_name":"叮当健康","start_time":0,"source_url":"","article_id":"1181425717","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181425717","pubTimestamp":1781259763,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Dingdang Health Technology Group Ltd. submitted a Next Day Disclosure Return on 12 June 2026, confirming that the company’s issued share capital remains unchanged at 1.25 billion ordinary shares,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09886":"叮当健康"},"translate_title":"叮当健康报告已回购895万股待注销；已发行资本稳定在12.5亿","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09886":1},"content_text":"Dingdang Health Technology Group Ltd. submitted a Next Day Disclosure Return on 12 June 2026, confirming that the company’s issued share capital remains unchanged at 1.25 billion ordinary shares, with no treasury shares outstanding.\nBetween 19 May and 12 June 2026 the company bought back a cumulative 8.95 million shares that have not yet been cancelled. The daily repurchase prices ranged from HK$0.82 to HK$0.96 per share, implying a cash outlay of roughly HK$8.02 million. The shares represent about 0.71 % of current issued shares.\nOn 12 June 2026 alone, Dingdang Health repurchased 54,500 shares on the Stock Exchange of Hong Kong at HK$0.90–0.91 per share, spending HK$49,229.85. These shares are designated for cancellation.\nUnder the share-repurchase mandate approved on 28 May 2025, the company is authorised to buy back up to 131.95 million shares (5.59 % of the share base at the mandate date). To date, 73.77 million shares have been repurchased under this mandate, utilising approximately 55.9 % of the authorised limit.\nIn line with listing rules, the company is subject to a moratorium on new share issues until 12 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181425717","isCrawlerRequest":true}